Literature DB >> 1389947

Pharmacokinetics of gamma-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses.

S D Ferrara1, S Zotti, L Tedeschi, G Frison, F Castagna, L Gallimberti, G L Gessa, P Palatini.   

Abstract

1. The pharmacokinetics of gamma-hydroxybutyric acid (GHB) were studied in 10 alcohol dependent subjects after single and repeated therapeutic oral doses (25 mg kg-1 every 12 h for 7 days). 2. GHB was readily absorbed and rapidly eliminated (tmax = 20-45 min; mean t1/2z 27 +/- 5 s.d. min). Urinary recovery of unchanged GHB was negligible (less than 1% of the dose). gamma-butyrolactone was not detected in either plasma or urine, indicating that lactonization of GHB does not occur in vivo. 3. The multiple-dose regimen resulted neither in accumulation of GHB nor in time-dependent modification of its pharmacokinetics. 4. In five subjects, the data were consistent with nonlinear elimination kinetics of GHB. Administration of a 50 mg kg-1 dose to these subjects resulted in significant increases in dose-normalized AUC, t1/2z and mean residence time. 5. Doubling of the dose also resulted in a significant increase in tmax with little change in Cmax. 6. At the administered doses, GHB did not accumulate in the plasma and caused no serious side effects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1389947      PMCID: PMC1381393          DOI: 10.1111/j.1365-2125.1992.tb04129.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  21 in total

1.  [Summary of an experimental and clinical study on a metabolic substrate with inhibitory central action: sodium 4-hydroxybutyrate].

Authors:  H LABORIT; J M JOUANY; J GERARD; F FABIANI
Journal:  Presse Med       Date:  1960-11-12       Impact factor: 1.228

2.  Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome.

Authors:  L Gallimberti; G Canton; N Gentile; M Ferri; M Cibin; S D Ferrara; F Fadda; G L Gessa
Journal:  Lancet       Date:  1989-09-30       Impact factor: 79.321

3.  Inhibitory effect of gammahydroxybutyric acid and gammaaminobutyric acid on the dopamine cells in the substantia nigra.

Authors:  N E Andén; G Stock
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

4.  Dopaminergic neurons: similar biochemical and histochemical effects of gamma-hydroxybutyrate and acute lesions of the nigro-neostriatal pathway.

Authors:  J R Walters; R H Roth; G K Aghajanian
Journal:  J Pharmacol Exp Ther       Date:  1973-09       Impact factor: 4.030

5.  Suppression by gamma-hydroxybutyric acid of ethanol withdrawal syndrome in rats.

Authors:  F Fadda; G Colombo; E Mosca; G L Gessa
Journal:  Alcohol Alcohol       Date:  1989       Impact factor: 2.826

6.  Dose-dependent pharmacokinetics and hypnotic effects of sodium gamma-hydroxybutyrate in the rat.

Authors:  J T Lettieri; H L Fung
Journal:  J Pharmacol Exp Ther       Date:  1979-01       Impact factor: 4.030

7.  A peek at the Child-Turcotte classification.

Authors:  H O Conn
Journal:  Hepatology       Date:  1981 Nov-Dec       Impact factor: 17.425

8.  Plasma and central nervous system kinetics of gamma-hydroxybutyrate.

Authors:  J S Shumate; O C Snead
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1979-08

9.  Ontogeny of gamma-hydroxybutyric acid. I. Regional concentration in developing rat, monkey and human brain.

Authors:  O C Snead; B J Morley
Journal:  Brain Res       Date:  1981-07       Impact factor: 3.252

10.  Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings.

Authors:  M Mamelak; M B Scharf; M Woods
Journal:  Sleep       Date:  1986       Impact factor: 5.849

View more
  23 in total

1.  Brain uptake of the drug of abuse γ-hydroxybutyric acid in rats.

Authors:  Samuel A Roiko; Melanie A Felmlee; Marilyn E Morris
Journal:  Drug Metab Dispos       Date:  2011-10-21       Impact factor: 3.922

Review 2.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

3.  Neuronal oscillations and synchronicity associated with gamma-hydroxybutyrate during resting-state in healthy male volunteers.

Authors:  Robin von Rotz; Michael Kometer; Dario Dornbierer; Jürg Gertsch; M Salomé Gachet; Franz X Vollenweider; Erich Seifritz; Oliver G Bosch; Boris B Quednow
Journal:  Psychopharmacology (Berl)       Date:  2017-04-20       Impact factor: 4.530

4.  Effect of chronic γ-hydroxybutyrate (GHB) administration on GHB toxicokinetics and GHB-induced respiratory depression.

Authors:  Bridget L Morse; Gurkishan S Chadha; Melanie A Felmlee; Kristin E Follman; Marilyn E Morris
Journal:  Am J Drug Alcohol Abuse       Date:  2017-06-29       Impact factor: 3.829

5.  Behavioral effects of gamma-hydroxybutyrate in humans.

Authors:  Alison Oliveto; William Brooks Gentry; Rhonda Pruzinsky; Kishorchandra Gonsai; Thomas R Kosten; Bridget Martell; James Poling
Journal:  Behav Pharmacol       Date:  2010-07       Impact factor: 2.293

6.  Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers.

Authors:  P Palatini; L Tedeschi; G Frison; R Padrini; R Zordan; R Orlando; L Gallimberti; G L Gessa; S D Ferrara
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

7.  Butanediol Conversion to Gamma-Hydroxybutyrate Markedly Reduced by the Alcohol Dehydrogenase Blocker Fomepizole.

Authors:  Evangelia Liakoni; Hallam Gugelmann; Delia A Dempsey; Timothy J Wiegand; Christopher Havel; Peyton Jacob; Neal L Benowitz
Journal:  Clin Pharmacol Ther       Date:  2019-01-08       Impact factor: 6.875

8.  Pharmacokinetics and pharmacodynamics of γ-hydroxybutyrate in healthy subjects.

Authors:  Matthias E Liechti; Boris B Quednow; Evangelia Liakoni; Dario Dornbierer; Robin von Rotz; Maria Salomé Gachet; Jürg Gertsch; Erich Seifritz; Oliver G Bosch
Journal:  Br J Clin Pharmacol       Date:  2016-02-25       Impact factor: 4.335

Review 9.  Pharmacological approaches to reducing craving in patients with alcohol use disorders.

Authors:  Carolina L Haass-Koffler; Lorenzo Leggio; George A Kenna
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

Review 10.  Gamma hydroxybutyric acid (GHB) for the treatment of alcohol dependence: a review.

Authors:  Fabio Caputo; Teo Vignoli; Icro Maremmani; Mauro Bernardi; Giorgio Zoli
Journal:  Int J Environ Res Public Health       Date:  2009-06-24       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.